You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Therapeutic Inhibition of BCL6 in Systemic Lupus Erythematosus

    SBC: L2 Diagnostics, LLC            Topic: NIAMS

    ABSTRACT Systemic autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus are characterized by polyclonal T cell activation driving the production of pathogenic class switched autoantibodiesThe class switchedsomatically mutated antibodies are generated from germinal centerGCB cellsA subset of effector CDT cellsknown as T follicular helperTfhcellshas been shown to play an ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Targeted Nanotherapy to Donor Organ Endothelia Modulates Early Immune Responses and Protects Against Late Graft Failure

    SBC: ToleRaM NanoTech LLC            Topic: NIBIB

    ABSTRACT Transplantation is an accepted and highly successful therapy for end stage organ diseaseWhile success rates and survival have risen steadilydue largely to improved immunosuppression regimesthere is a growing appreciation that damage and inflammation that occur early in the life of the graftsignificantly impact chronic rejection and thus long term survivalCentral to these early event injur ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Structure-guided optimization of an in vivo active small molecule antitubercular targeting KasA

    SBC: COLLABORATIONS PHARMACEUTICALS, INC.            Topic: NIAID

    Project Summary The continued spread of drug resistant Mycobacterium tuberculosisMtbinfections has rendered tuberculosisTBa global health pandemic and pressed home the urgent need for new drugsCompounds which inhibit essential components of the Mtb cell wall rapidly cause cell death and are represented clinically by isoniazidIf any drug combination is likely to reduce treatment duration and preven ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Small Molecule Anti-Inflammatories for Ocular Graft Versus Host Disease

    SBC: Eyedesis Biosciences, LLC            Topic: NEI

    PROJECT SUMMARYABSTRACT Ocular graft versus host diseaseOGVHDis a severe ocular surface inflammatory diseaseOSIDoccurring in patients undergoing allogenic hematopoietic stem cell transplantationHSCTOGVHD is characterized by dry eyemeibomian gland dysfunctionconjunctival scarringlid margin scarringkeratopathyand corneal ulcerationcausing significant ocular morbidity and vision loss for affected pat ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. RNA Detection as an Improved Diagnostic Assay for Human Leptospirosis

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Leptospirosis a zoonotic disease is an important public health problem worldwide It is caused by spirochete bacteria belonging to nine species and more than serovars of the genus Leptospira In the US there is increasing awareness of the importance of leptospirosis as the cause of disease among inner city populations military personnel and individuals ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Reprogrammed T Cells to prevent graft versus host disease

    SBC: Element Genomics, Inc.            Topic: NIAID

    PROJECT SUMMARY ABSTRACT The objective of this proposal is to develop an efficient and robust method to epigenetically reprogram na ve human T cells into regulatory T cellsTregsthat can prevent graft versus host diseaseGvHDOur short term goal for Phase I of the STTR award is to demonstrate that we can epigenetically reprogram na ve T cells using CRISPR Casbased technology into immunosuppressive ce ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Removal of Amyloid-beta Peptides from the Alzheimer's Brain

    SBC: WE BIOSCIENCES, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): As the Alzheimer's disease (AD) population is growing rapidly, currently there are no cure treatments. The goal of this resubmitted STTR proposal is to conduct a preclinical study with pramlintide to prove a potential treatment for AD. We have revised the proposal significantly according to the reviewers' comments. Pramlintide is an FDA approved drug ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Reactor for Insect Cell Culture

    SBC: Glycan Therapeutics LLC            Topic: 300

    This fast track STTR application proposes to synthesize structurally defined heparan sulfate and chondroitin sulfate oligosaccharides for biological researchGlycan Therapeutics is a biotech company specializing in synthesizing sulfated carbohydrates using innovative enzyme based methodsThis proposal is focused on the synthesis of large authentic oligosaccharides in the size range ofmers tomersas w ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Quantifying NETosis via Automated High Content Imaging Convolutional Neural Networks

    SBC: Epicypher, Inc.            Topic: NIAID

    PROJECT SUMMARY NETosis was identified as a distinct mode of cell death in neutrophils more than a decade agoDysregulation of NETosis has been implicated in the etiology of human pathologies such as preeclampsiasickle cell diseasesystemic lupus erythematosusmultiple sclerosisrheumatoid arthritissepsiscystic fibrosislupus nephritisand coagulopathies that include cancer associated thrombosisThe lite ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. POC 2-D Diffusion Assay for self-monitoring of BNP

    SBC: SENTILUS            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of this STTR proposal is to develop a 2-D diffusion point-of-care assay (POC) for B-type natriuretic peptide (BNP). The primary goal of the proposed work is to create a test format that will allow patientswith chronic heart failure to quantitatively self-monitor serum levels of BNP. Determination of baseline level of BNP and changes in this level ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government